Literature DB >> 28802941

The Epidemiology of Nonmotor Symptoms in Parkinson's Disease (Cohort and Other Studies).

Elena Katunina1, Nataliya Titova2.   

Abstract

Nonmotor symptoms (NMS) of Parkinson's disease (PD) were recognized by James Parkinson himself and are now considered to be an integral part of PD. While clinical assessment had focused on prevalence and severity of individual NMS such as dementia and depression, work in the last decade has concentrated on global or holistic assessment of NMS using validated tools such as the NMS questionnaire and NMS scale. These studies from cohorts of varying sizes have allowed comparison of NMS across different disease stages, duration, age, and ethnicity in PD. The data also allow exploration of the concept of the nonlinear relationship of NMS to disease duration of PD and motor stages as well as nonmotor subtypes of PD. In this chapter, these aspects of epidemiological studies of NMS in PD cohorts are described.
© 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cohort; Holistic; Nonmotor symptoms; Parkinson's disease; Prevalence

Mesh:

Year:  2017        PMID: 28802941     DOI: 10.1016/bs.irn.2017.05.012

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  6 in total

1.  "New methods of assessing autonomic disorders in Parkinson disease patients: skin-galvanic reaction".

Authors:  Justyna Dutkiewicz; Stanisław Szlufik; Andrzej Friedman
Journal:  J Neural Transm (Vienna)       Date:  2019-09-28       Impact factor: 3.575

2.  Prevalence of Non-Motor Symptoms and Non-Motor Fluctuations in Parkinson's Disease Using the MDS-NMS.

Authors:  Carmen Rodriguez-Blazquez; Anette Schrag; Alexandra Rizos; K Ray Chaudhuri; Pablo Martinez-Martin; Daniel Weintraub
Journal:  Mov Disord Clin Pract       Date:  2020-12-21

Review 3.  Natural Compounds as Medical Strategies in the Prevention and Treatment of Psychiatric Disorders Seen in Neurological Diseases.

Authors:  Esra Küpeli Akkol; Irem Tatlı Çankaya; Gökçe Şeker Karatoprak; Elif Carpar; Eduardo Sobarzo-Sánchez; Raffaele Capasso
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

Review 4.  Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.

Authors:  Federico Carbone; Atbin Djamshidian; Klaus Seppi; Werner Poewe
Journal:  CNS Drugs       Date:  2019-09       Impact factor: 5.749

5.  A Pitx3-deficient developmental mouse model for fine motor, olfactory, and gastrointestinal symptoms of Parkinson's disease.

Authors:  Bin Song; Jacob W Feldmann; Shibo Cao; Melissa Feitosa; Youngbin Kong; Woori Kim; Altana Schweitzer; Pierre Leblanc; Jeffrey S Schweitzer; Kwang-Soo Kim
Journal:  Neurobiol Dis       Date:  2022-05-27       Impact factor: 7.046

6.  Motor Cortex Stimulation Reversed Hypernociception, Increased Serotonin in Raphe Neurons, and Caused Inhibition of Spinal Astrocytes in a Parkinson's Disease Rat Model.

Authors:  Ana Carolina P Campos; Miriã B Berzuíno; Gabriela R Barbosa; Helena M R C Freire; Patricia S Lopes; Danielle V Assis; Erich T Fonoff; Rosana L Pagano
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.